Activity restriction in mild COPD: A challenging clinical problem

International Journal of COPD

Volumn 9, Issue , 2014, Pages 577-588

  O'Donnell, Denis E ^a   Gebke, Kevin B ^b  

^a KINGSTON GENERAL HOSPITAL   (Canada)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic obstructive pulmonary disease (COPD); Dyspnea; Exercise; Physical activity; Small airway dysfunction

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING DRUG; SHORT ACTING DRUG;

6 MINUTE WALKING DISTANCE TEST; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; ENDURANCE SHUTTLE WALKING TEST; ENDURANCE TRAINING; EXERCISE; EXERCISE TEST; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; HUMAN; INCREMENTAL SHUTTLE WALKING TEST; MUSCLE DISEASE; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; SKELETAL MUSCLE; SMOKING CESSATION; TREATMENT RESPONSE; ACTIMETRY; LUNG; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX;

ACTIGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; HUMANS; LUNG; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84902009684     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S62766     Document Type: Review

References (116)

1. Global Strategy for Diagnosis, Management, and Prevention of COPD. Global initiative for chronic Obstructive Lung Disease (GOLD); updated 2014. Available from: http://www.goldcopd.org/. Accessed January 27, 2014.
2. Morbidity and Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Heart, Lung, and Blood Institute; 2009. Available from: http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf. Accessed January 27, 2014.
3. Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis. 2011;6:573-581.
4. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63:402-407.
5. Troosters T, Sciurba F, Battaglia S, etal. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med. 2010;104:1005-1011.
6. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61:772-778.
7. ten Hacken NH. Physical inactivity and obesity: relation to asthma and chronic obstructive pulmonary disease? Proc Am Thorac Soc. 2009;6: 663-667.
8. Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. J Leukoc Biol. 2005;78:819-835.
9. Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM; Estudi del Factors de Risc d'Agudització de la MPOC investigators. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58:100-105.
10. Guenette JA, Jensen D, Webb KA, Ofir D, Raghavan N, O'Donnell DE. Sex differences in exertional dyspnea in patients with mild COPD: physiological mechanisms. Respir Physiol Neurobiol. 2011;177: 218-227.
11. Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(6):622-629.
12. Díaz AA, Morales A, Díaz JC, etal. CT and physiologic determinants of dyspnea and exercise capacity during the six-minute walk test in mild COPD. Respir Med. 2013;107:570-579.
13. ZuWallack R. How are you doing? What are you doing? Differing perspectives in the assessment of individuals with COPD. COPD. 2007;4:293-297.
14. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675-679.
15. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233-239.
16. Qaseem A, Wilt TJ, Weinberger SE, etal; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179-191.
17. O'Donnell DE, Aaron S, Bourbeau J, etal. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J. 2007;14 Suppl B:5B-32B.
18. Chin RC, Guenette JA, Cheng S, etal. Does the respiratory system limit exercise in mild chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2013;187:1315-1323.
19. McDonough JE, Yuan R, Suzuki M, etal. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365:1567-1575.
20. Nici L, Donner C, Wouters E, etal; ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390-1413.
21. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:972-977.
22. O'Donnell DE. Ventilatory limitations in chronic obstructive pulmonary disease. Med Sci Sports Exerc. 2001;33:S647-S655.
23. Saey D, Michaud A, Couillard A, etal. Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:1109-1115.
24. Man WD, Soliman MG, Gearing J, etal. Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168:562-567.
25. Palange P, Forte S, Onorati P, Manfredi F, Serra P, Carlone S. Ventilatory and metabolic adaptations to walking and cycling in patients with COPD. J Appl Physiol (1985). 2000;88:1715-1720.
26. Pepin V, Saey D, Whittom F, LeBlanc P, Maltais F. Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:1517-1522.
27. Maltais F, Hamilton A, Marciniuk D, etal. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128:1168-1178.
28. O'Donnell DE, Flüge T, Gerken F, etal. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832-840.
29. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004;24:86-94.
30. Matsuoka S, Washko GR, Dransfield MT, etal. Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations with emphysema and airflow limitation. Acad Radiol. 2010;17:93-99.
31. Rambod M, Porszasz J, Make BJ, Crapo JD, Casaburi R. Six-minute walk distance predictors, including CT scan measures, in the COPDGene cohort. Chest. 2012;141:867-875.
32. Yuan R, Hogg JC, Paré PD, etal. Prediction of the rate of decline in FEV(1) in smokers using quantitative computed tomography. Thorax. 2009;64:944-949.
33. Deesomchok A, Webb KA, Forkert L, etal. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD. 2010;7:428-437.
34. Gagnon P, Guenette JA, Langer D, etal. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:187-201.
35. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968;278: 1355-1360.
36. Hogg JC, Chu F, Utokaparch S, etal. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-2653.
37. Black LF, Hyatt RE, Stubbs SE. Mechanism of expiratory airflow limitation in chronic obstructive pulmonary disease associated with 1-antitrypsin deficiency. Am Rev Respir Dis. 1972;105:891-899.
38. Leaver DG, Tatterfield AE, Pride NB. Contributions of loss of lung recoil and of enhanced airways collapsibility to the airflow obstruction of chronic bronchitis and emphysema. J Clin Invest. 1973;52:2117-2128.
39. Mitzner W. Emphysema-a disease of small airways or lung parenchyma? N Engl J Med. 2011;365:1637-1639.
40. Corbin RP, Loveland M, Martin RR, Macklem PT. A four-year follow-up study of lung mechanics in smokers. Am Rev Respir Dis. 1979;120:293-304.
41. Barbera JA, Ramirez J, Roca J, Wagner PD, Sanchez-Lloret J, Rodriguez-Roisin R. Lung structure and gas exchange in mild chronic obstructive pulmonary disease. Am Rev Respir Dis. 1990;141:895-901.
42. Barberà JA, Riverola A, Roca J, etal. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;149:423-429.
43. Rodríguez-Roisin R, Drakulovic M, Rodríguez DA, Roca J, Barberà JA, Wagner PD. Ventilation-perfusion imbalance and chronic obstructive pulmonary disease staging severity. J Appl Physiol (1985). 2009;106: 1902-1908.
44. Santos S, Peinado VI, Ramírez J, etal. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002;19:632-638.
45. O'Donnell DE, Laveneziana P, Ora J, Webb KA, Lam YM, Ofir D. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax. 2009;64:216-223.
46. O'Donnell DE, Maltais F, Porszasz J, etal. Lung function and exercise impairment in patients with GOLD stage I and II COPD. Am J Respir Crit Care Med. Conference, 18-23 May, 2012, San Francisco, California, USA. Abstr. No. D80.
47. Peinado VI, Barbera JA, Ramirez J, etal. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol. 1998;274:L908-L913.
48. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc.1982;14(5);377-381.
49. McParland C, Mink J, Gallagher CG. Respiratory adaptations to dead space loading during maximal incremental exercise. J Appl Physiol (1985). 1991;70:55-62.
50. O'Donnell DE, Hong HH, Webb KA. Respiratory sensation during chest wall restriction and dead space loading in exercising men. J Appl Physiol (1985). 2000;88:1859-1869.
51. Syabbalo NC, Zintel T, Watts R, Gallagher CG. Carotid chemoreceptors and respiratory adaptations to dead space loading during incremental exercise. J Appl Physiol (1985). 1993;75:1378-1384.
52. Brown SE, King RR, Temerlin SM, Stansbury DW, Mahutte CK, Light RW. Exercise performance with added dead space in chronic airflow obstruction. J Appl Physiol Respir Environ Exerc Physiol. 1984;56:1020-1026.
53. Barr RG, Bluemke DA, Ahmed FS, etal. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362:217-227.
54. Grau M, Barr RG, Lima JA, etal. Percent emphysema and right ventricular structure and function: the Multi-Ethnic Study of Atherosclerosis-Lung and Multi-Ethnic Study of Atherosclerosis-Right Ventricle Studies. Chest. 2013;144:136-144.
55. Malerba M, Ragnoli B, Salameh M, etal. Sub-clinical left ventricular diastolic dysfunction in early stage of chronic obstructive pulmonary disease. J Biol Regul Homeost Agents. 2011;25:443-451.
56. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100:115-122.
57. Sabit R, Bolton CE, Fraser AG, etal. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med. 2010;104:1171-1178.
58. Smith BM, Kawut SM, Bluemke DA, etal. Pulmonary hyperinflation and left ventricular mass: the Multi-Ethnic Study of Atherosclerosis COPD Study. Circulation. 2013;127:1503-1511.
59. Thomashow MA, Shimbo D, Parikh MA, etal. Endothelial microparticles in mild chronic obstructive pulmonary disease and emphysema. The Multi-Ethnic Study of Atherosclerosis Chronic Obstructive Pulmonary Disease study. Am J Respir Crit Care Med. 2013;188:60-68.
60. Lange P, Marott JL, Vestbo J, etal. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186:975-981.
61. Roig M, Eng JJ, MacIntyre DL, Road JD, Reid WD. Deficits in muscle strength, mass, quality, and mobility in people with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev. 2011;31:120-124.
62. Orozco-Levi M, Coronell C, Ramírez-Sarmiento A, etal. Injury of peripheral muscles in smokers with chronic obstructive pulmonary disease. Ultrastruct Pathol. 2012;36:228-238.
63. van den Borst B, Slot IG, Hellwig VA, etal. Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild-to-moderate COPD. J Appl Physiol (1985). 2013;114:1319-1328.
64. Clark CJ, Cochrane LM, Mackay E, Paton B. Skeletal muscle strength and endurance in patients with mild COPD and the effects of weight training. Eur Respir J. 2000;15:92-97.
65. Seymour JM, Spruit MA, Hopkinson NS, etal. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J. 2010;36:81-88.
66. Vogiatzis I, Zakynthinos S. The physiological basis of rehabilitation in chronic heart and lung disease. J Appl Physiol (1985). 2013;115: 16-21.
67. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J. 2006;27:1040-1055.
68. Moore R, Berlowitz D, Denehy L, Jackson B, McDonald CF. Comparison of pedometer and activity diary for measurement of physical activity in chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev. 2009;29:57-61.
69. Maltais F. Exercise and COPD: therapeutic responses, disease-related outcomes, and activity-promotion strategies. Phys Sportsmed. 2013;41:66-80.
70. Le Masurier GC, Tudor-Locke C. Comparison of pedometer and accelerometer accuracy under controlled conditions. Med Sci Sports Exerc. 2003;35:867-871.
71. Pitta F, Troosters T, Spruit MA, Decramer M, Gosselink R. Activity monitoring for assessment of physical activities in daily life in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2005;86:1979-1985.
72. Patel SA, Benzo RP, Slivka WA, Sciurba FC. Activity monitoring and energy expenditure in COPD patients: a validation study. COPD. 2007;4:107-112.
73. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33:262-272.
74. Waschki B, Kirsten A, Holz O, etal. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331-342.
75. Lacasse Y, Martin S, Lasserson TJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. A Cochrane systematic review. Eura Medicophys. 2007;43:475-485.
76. Worth H, Förster K, Eriksson G, Nihlén U, Peterson S, Magnussen H. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med. 2010;104:1450-1459.
77. Maltais F, Celli B, Casaburi R, etal. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011;105:580-587.
78. O'Donnell DE, Casaburi R, Vincken W, etal. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105:1030-1036.
79. Borel B, Provencher S, Saey D, Maltais F. Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. Pulm Med. 2013;2013:410748.
80. Belfer MH, Reardon JZ. Improving exercise tolerance and quality of life in patients with chronic obstructive pulmonary disease. J Am Osteopath Assoc. 2009;109:268-278.
81. Garrod R, Bestall JC, Paul EA, Wedzicha JA, Jones PW. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med. 2000;94:589-596.
82. Janaudis-Ferreira T, Beauchamp MK, Robles PG, Goldstein RS, Brooks D. Measurement of activities of daily living in patients with COPD: a systematic review. Chest. 2014;145:253-271.
83. Doherty DE, Belfer MH, Brunton SA, Fromer L, Morris CM, Snader TC. Chronic obstructive pulmonary disease: consensus recommendations for early diagnosis and treatment. J Fam Pract Clinical update. 2006;55(Suppl):S1-S8.
84. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648-654.
85. Jones PW, Brusselle G, Dal Negro RW, etal. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38:29-35.
86. Powrie DJ. The BODE index: a new grading system in COPD. Thorax. 2004;59:427.
87. Celli BR, Cote CG, Marin JM, etal. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005-1012.
88. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-117.
89. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest. 2001;119:256-270.
90. Golpe R, Pérez-de-Llano LA, Méndez-Marote L, Veres-Racamonde A. Prognostic value of walk distance, work, oxygen saturation, and dyspnea during 6-minute walk test in COPD patients. Respir Care. 2013;58:1329-1334.
91. Casanova C, Cote C, Marin JM, etal. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest. 2008;134:746-752.
92. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004;23:28-33.
93. Ilgin D, Ozalevli S, Kilinc O, Sevinc C, Cimrin AH, Ucan ES. Gait speed as a functional capacity indicator in patients with chronic obstructive pulmonary disease. Ann Thorac Med. 2011;6:141-146.
94. Morgan MD, Singh SJ. Assessing the exercise response to a bronchodilator in COPD: time to get off your bike? Thorax. 2007;62: 281-283.
95. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax. 1992;47:1019-1024.
96. Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax. 1999;54: 213-222.
97. Pepin V, Brodeur J, Lacasse Y, etal. Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease. Thorax. 2007;62:291-298.
98. Brouillard C, Pepin V, Milot J, Lacasse Y, Maltais F. Endurance shuttle walking test: responsiveness to salmeterol in COPD. Eur Respir J. 2008;31:579-584.
99. Boer LM, Asijee GM, van Schayck OC, Schermer TR. How do dyspnoea scales compare with measurement of functional capacity in patients with COPD and at risk of COPD? Prim Care Respir J. 2012;21:202-207.
100. O'Donnell DE, Maltais F, Porszasz J, etal. The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trial. PLoS ONE. 2014;9(5):e96574.
101. Maltais F, Dennis N, Chan CK. Rationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPD. COPD. 2013;10:79-103.
102. Calverley PM, Anderson JA, Celli B, etal. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.
103. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171-1178.
104. Jenkins CR, Jones PW, Calverley PM, etal. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
105. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153: 967-975.
106. O'Donnell DE, Sciurba F, Celli B, etal. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130:647-656.
107. Peters MM, Webb KA, O'Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. Thorax. 2006;61:559-567.
108. Raghavan N, Guenette JA, O'Donnell DE. The role of pharmacotherapy in mild to moderate chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2011;5:245-254.
109. Ferguson GT. Maintenance pharmacotherapy of mild and moderate COPD: what is the evidence? Respir Med. 2011;105:1268-1274.
110. Gagnon P, Saey D, Provencher S, etal. Walking exercise response to bronchodilation in mild COPD: a randomized trial. Respir Med. 2012;106:1695-1705.
111. Nici L, Lareau S, ZuWallack R. Pulmonary rehabilitation in the treatment of chronic obstructive pulmonary disease. Am Fam Physician. 2010;82:655-660.
112. Tselebis A, Bratis D, Pachi A, etal. A pulmonary rehabilitation program reduces levels of anxiety and depression in COPD patients. Multidiscip Respir Med. 2013;8:41.
113. Bratås O, Espnes GA, Rannestad T, Walstad R. Pulmonary rehabilitation reduces depression and enhances health-related quality of life in COPD patients-especially in patients with mild or moderate disease. Chron Respir Dis. 2010;7:229-237.
114. Chavannes N, Vollenberg JJ, van Schayck CP, Wouters EF. Effects of physical activity in mild to moderate COPD: a systematic review. Br J Gen Pract. 2002;52:574-578.
115. Jácome CI, Marques AS. Pulmonary rehabilitation for mild chronic obstructive pulmonary disease: A systematic review. Respir Care. 2014 Apr;59(4):588-594.
116. Martinez FJ, Raczek AE, Seifer FD, etal; COPD-PS Clinician Working Group. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD. 2008;5: 85-95.